Clinical Trials Sponsored by Julius Wolff Institute

Total 158 results

Prof. Dr. Carsten Perka
Julius Wolff Institute

Unknown

In-vivo Comparison of Different Levels of Femoral Rollback in a Primary Total Knee Arthroplasty (DePuyAttune)

Gonarthrosis

Germany
Jules Bordet Institute
AstraZeneca; Institut Curie

Active, not recruiting

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)

Luminal B

France, Belgium
Jules Bordet Institute

Not yet recruiting

Evaluation of the RESTART Survival Programme

Invasive Breast Cancer
Jules Bordet Institute

Recruiting

Multidisciplinary Approach to Fatigue

Breast Cancer | Germ Cell Tumor

Belgium
Jules Bordet Institute

Recruiting

Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy (SwallPEG)

Oropharyngeal Cancer

Belgium
Jules Bordet Institute

Completed

Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption (DESIGN)

Locoregional Analgesia in Breast Surgery

Belgium
Jules Bordet Institute

Completed

Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) (RegARd-C)

Advanced Chemorefractory Colorectal Adenocarcinoma

Belgium
Jules Bordet Institute

Withdrawn

Kadcyla In pAtients With bRAin Metastasis (KIARA)

Metastatic HER2-positive Breast Cancer With Brain Metastasis
Jules Bordet Institute

Completed

Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Belgium
Jules Bordet Institute

Completed

Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Head and Neck Neoplasms

Belgium
Jules Bordet Institute

Unknown

Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia (PAPALDO)

Breast Cancer

Belgium
Jules Bordet Institute

Unknown

NIR Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After iv Injection of ICG

Head and Neck Cancer

Belgium
Jules Bordet Institute

Unknown

Evaluation of Two Techniques for the SLN Detection in BC Patients

Breast Cancer

Belgium
Jules Bordet Institute

Unknown

Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia (ASCI)

Effects of Immunotherapy | Acute Myelogenous Leukemia | Myeloid Leukemia in Remission

Belgium
Jules Bordet Institute

Recruiting

ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study (BREASTIFLU-1)

Breast Cancer

Belgium
Jules Bordet Institute

Recruiting

Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors (LIFE)

Non Small Cell Lung Cancer

Belgium
Jules Bordet Institute

Recruiting

Efficacy and Safety of SCRT Versus TNT in Older Patients With Locally Advanced Rectal Cancer (SHAPERS)

Older People | Locally Advanced Rectal Cancer

Belgium
Jules Bordet Institute

Not yet recruiting

To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT (SQUAL)

Gynecologic Cancer
Jules Bordet Institute

Not yet recruiting

Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.

Radiation Toxicity | Radiodermatitis | Radiotherapy Side Effect
Jules Bordet Institute

Recruiting

Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients (SCARLET)

Multiple Myeloma

Belgium
Jules Bordet Institute

Completed

Effects of Oxygen After Abdominal Oncological Surgery (EPHIRAS)

Abdominal Cancer

Belgium
Jules Bordet Institute

Active, not recruiting

PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) (PROCAR-BQ)

Quality of Life | Prostate Cancer | Radiotherapy Side Effect | Bowel Dysfunction

Belgium
Jules Bordet Institute

Completed

Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy

Breast Cancer

Belgium
Jules Bordet Institute

Completed

Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer (PePiTA)

Colon Cancer

Belgium
Jules Bordet Institute

Completed

Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) (NeoRHEA)

Breast Cancer Female

Belgium
Jules Bordet Institute

Completed

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (LUMEN)

Gastroenteropancreatic Neuroendocrine Tumors

Belgium
Jules Bordet Institute

Withdrawn

Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer (NeraBrain)

Breast Cancer | Brain Metastases
Jules Bordet Institute

Completed

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (PRECISION-F)

Metastatic Melanoma | Colorectal Cancer Metastatic | Metastatic Non-Small Cell Lung Carcinoma

Belgium
Jules Bordet Institute

Withdrawn

Randomized Phase III of PRRT Versus Interferon (CASTOR)

Gastro-intestinal Neuroendocrine Tumors

Belgium
Jules Bordet Institute

Withdrawn

TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen (TRIUMPH)

Breast Cancer

Belgium
Jules Bordet Institute

Completed

Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients (OV-AP-ICG-IV)

Ovarian Cancer | Peritoneal Carcinomatosis

Belgium
Jules Bordet Institute

Unknown

Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy

Breast Cancer

Belgium
Jules Bordet Institute

Completed

Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer

Invasive Breast Cancer

Belgium
Jules Bordet Institute

Completed

Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer (EndoTAG-1)

Breast Cancer

Belgium
Jules Bordet Institute

Completed

PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome. (earlyPETmCRC)

Colorectal Cancer Metastatic | Early Response Evaluation | Fdg-PET

Belgium
Jules Bordet Institute

Completed

PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2

Carcinoma Breast Stage IV

Belgium
Jules Bordet Institute

Recruiting

Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis (FAPeCa)

Cancer | Peritoneal Carcinomatosis

Belgium
Jules Bordet Institute

Recruiting

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. (PRISMA)

TNBC - Triple-Negative Breast Cancer

Belgium
Jules Bordet Institute

Recruiting

Assessment of (Chemo)RT-related Dysphagia in HNC Patients Based on Cough-related Acoustic Features

Head and Neck Cancer | Dysphagia

Belgium
Jules Bordet Institute

Recruiting

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Melanoma | Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Mesothelioma, Malignant | Bladder Cancer | Gastrointestinal Cancer | Merkel Cell Carcinoma | Non-melanoma Skin Cancer | MSI-H Colorectal Cancer

Belgium
Jules Bordet Institute

Recruiting

Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (REGINA)

Rectal Cancer Stage II | Rectal Cancer Stage III

Belgium, France
Jules Bordet Institute

Completed

Inferior Epigastric Lymph Node in Colorectal Carcinosis (EpiLyPath)

Colorectal Carcinomatosis

Belgium
Jules Bordet Institute

Completed

Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal Metastases (OvEpiLyPath)

Carcinomatosis, Peritoneal

Belgium
Jules Bordet Institute

Active, not recruiting

Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer (StomRay)

Head and Neck Squamous Cell Carcinoma

Belgium
Jules Bordet Institute

Completed

Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer (CORIOLAN)

Colorectal Cancer

Belgium
Jules Bordet Institute

Active, not recruiting

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

Breast Cancer

United States, Belgium, Israel, France, Italy, Spain, Brazil, Mexico, Poland, Portugal, Switzerland
Jules Bordet Institute

Completed

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers (MOMENTUM1)

Metastatic Colorectal Cancers | Metastatic Gastric Cancers | Metastatic Oesophageal Cancers | Metastatic Pancreatic Cancers | Metastatic Biliary Cancers | Metastatic Breast Cancers

Belgium
Jules Bordet Institute

Withdrawn

Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management (ProsPERo)

Prostate Cancers
Jules Bordet Institute

Completed

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients (IJBMNZrT003)

Breast Neoplasms | Secondary | HER2 Positive Carcinoma of Breast

Belgium
Jules Bordet Institute

Withdrawn

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer (RHEA)

Breast Cancer

Belgium, France

3

Subscribe